BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cumberland Pharmaceuticals Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Cumberland Pharmaceuticals Inc.'s
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05571059-4592@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ifetroban: Phase 2 readout est. (NCT05571059)
DESCRIPTION:Ifetroban\, phase 2.\nStudy: Oral Ifetroban in Patients With Id
 iopathic Pulmonary Fibrosis (IPF)\nEstimated primary completion: January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ifetroban#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05571059
URL:https://assetmemo.bio/drug/ifetroban#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
